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Evaluation of Diffuse Myocardial
Fibrosis in Heart Failure With Cardiac
Magnetic Resonance Contrast-Enhanced T1 Mapping
Leah Iles, MBCHB,* Heinz Pfluger, MD,* Arintaya Phrommintikul, MD,*
Joshi Cherayath, DIP AMIT,† Pelin Aksit, MS,‡ Sandeep N. Gupta, PHD,‡ David M. Kaye, PHD,*
Andrew J. Taylor, PHD*
Melbourne, Australia; and Bethesda, Maryland
Objectives The purpose of this study was to investigate a noninvasive method for quantifying diffuse myocardial fibrosis
with cardiac magnetic resonance imaging (CMRI).
Background Diffuse myocardial fibrosis is a fundamental process in pathologic remodeling in cardiomyopathy and is postu-
lated to cause increased cardiac stiffness and poor clinical outcomes. Although regional fibrosis is easily imaged
with cardiac magnetic resonance, there is currently no noninvasive method for quantifying diffuse myocardial
fibrosis.
Methods We performed CMRI on 45 subjects (25 patients with heart failure, 20 control patients), on a clinical 1.5-T CMRI
scanner. A prototype T1 mapping sequence was used to calculate the post-contrast myocardial T1 time as an
index of diffuse fibrosis; regional fibrosis was identified by delayed contrast enhancement. Regional and global
systolic function was assessed by cine CMRI in standard short- and long-axis planes, with echocardiography
used to evaluate diastology. An additional 9 subjects underwent CMRI and endomyocardial biopsy for histologic
correlation.
Results Post-contrast myocardial T1 times correlated histologically with fibrosis (R  0.7, p  0.03) and were shorter
in heart failure subjects than controls (383  17 ms vs. 564  23 ms, p  0.0001). The T1 time of heart failure
myocardium was shorter than that in controls even when excluding areas of regional fibrosis (429  22 ms vs.
564  23 ms, p  0.0001). The post-contrast myocardial T1 time shortened as diastolic function worsened (562
 24 ms in normal diastolic function vs. 423  33 ms in impaired diastolic function vs. 368  20 ms in restric-
tive function, p  0.001).
Conclusions Contrast-enhanced CMRI T1 mapping identifies changes in myocardial T1 times in heart failure, which appear to
reflect diffuse fibrosis. (J Am Coll Cardiol 2008;52:1574–80) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.049s
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teart failure is a major cause of morbidity and mortality in
he western world, causing over 1,000,000 hospitalizations/
ear in the U.S. (1). Although many advances have occurred
n the medical management of systolic heart failure in the
ast 20 years, many patients ultimately progress to end-stage
ardiomyopathy.
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ia. Dr. Pfluger is supported by a research grant from the Swiss National Science
oundation SNSF, Bern, Switzerland. Joshi Cherayath, Pelin Aksit, and Dr. Gupta
re employees of GE Healthcare. Drs. Iles and Pfluger contributed equally to this
ork.g
Manuscript received February 13, 2008; revised manuscript received May 8, 2008,
ccepted June 10, 2008.The heavy burden of heart failure necessitates further re-
earch into the basic pathophysiology of this growing epi-
emic. Recently, the importance of myocardial fibrosis in
evelopment and progression of systolic and diastolic cardiac
ailure has been highlighted (2,3). Myocardial fibrosis in
nimals is associated with worsening ventricular systolic
See page 1581
unction, abnormal cardiac remodeling, and increased ventric-
lar stiffness (4). The link between collagen turnover and
yocardial fibrosis is not fully understood, but it is thought to
lay an important role in the development of diastolic dysfunc-
ion (5,6). Also, increasing myocardial fibrosis results in pro-
ressive deterioration of myocardial function, with more
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November 4, 2008:1574–80 Quantifying Fibrosis in Heart Failurextensive myocardial fibrosis identified in patients with ad-
anced heart failure, regardless of etiology of cardiomyopathy
7–9). A number of available therapies have been postulated to
xert some of their beneficial effects via inhibition of myocar-
ial fibrosis, principally through their actions on the renin-
ngiotensin-aldosterone system (10–13).
Regional myocardial fibrosis due to ischemic heart disease
s well described with delayed contrast enhancement se-
uences on cardiac magnetic resonance imaging (CMRI)
14,15). Infarcted regions in the myocardium, having un-
ergone scar formation with collagen deposition, have a
uch slower washout rate of gadolinium-based contrast
han healthy myocardium, leading to a markedly increased
ignal intensity on T1-weighted imaging. A critical draw-
ack to the technique of delayed contrast-enhanced CMRI
n the detection of more diffuse myocardial fibrosis is that it
s qualitative, not quantitative, and it relies on the difference
n signal intensity between scarred and normal adjacent
yocardium to generate image contrast. Because collagen
eposition in nonischemic cardiomyopathy is commonly
iffuse, the technique of delayed contrast enhancement
ften shows no regional scarring. A noninvasive test for
yocardial fibrosis is highly desirable, not just in terms of
isease stratification, but also in evaluating newer therapies
imed at reducing myocardial fibrosis in the treatment of heart
ailure.
Theoretically, diffusely fibrotic myocardium would accu-
ulate contrast in a similar fashion to regional scarring, but
alculation of the global T1 time is required for its quanti-
cation. Studies in canine myocardium have identified
lteration of the T1 time with fibrosis (16), which correlated
ith myocardial collagen content. Similar findings have
een demonstrated in hypertensive rat hearts (17) and in
uman papillary muscles (18).
In this prospective study we investigated the correlation
etween histologic fibrosis and myocardial post-contrast T1
ime. We also calculated the post-contrast T1 time as an
ndex of diffuse fibrosis in a group of heart failure subjects
nd controls and report an important mechanistic link
etween structural myocardial changes and functional im-
airment in heart failure.
ethods
atient selection. All research was performed through the
lfred Hospital, Melbourne, Australia between March
006 and December 2006. Subjects with heart failure of
ew York Heart Association functional class II or worse
ere invited to participate. Subjects with normal left ven-
ricular function and no symptoms of heart failure were
ecruited as a control group. In all instances, subjects were
xcluded if they suffered from claustrophobia, uncontrolled
trial or ventricular tachyarrhythmias, or had a history of a
etallic prosthetic implant contraindicating CMRI. Pa-ients with recent myocardial infarction or myocarditis were elso excluded. No subject invited
nto either group declined to
articipate.
Endomyocardial biopsies and
MRI results were analyzed in
n additional group of subjects
ith previous orthotopic heart
ransplantation. Subjects were
xcluded if they had acute rejec-
ion, were clinically unstable, or
ad a contraindication to CMRI.
his group was not included in
he overall analysis because 8 of
he 9 subjects had preserved left
entricular systolic function, so
ere not suitable for inclusion in
he heart failure group. Because
hey were not free of cardiac
isease and would be expected to
ave a greater degree of myocar-
ial fibrosis than a control popu-
ation, they were also not appro-
riate for the control group.
Informed consent was ob-
ained before CMRI for all participants, and the study was
arried out under the guidelines of the Alfred Hospital
thics Committee.
istologic analysis. Transvenous right ventricular endo-
yocardial biopsy specimens from a separate group of
ubjects (n  9) were fixed immediately in 10% buffered
ormalin, embedded in paraffin, routinely processed, and
tained with picrosirius red to obtain contrast between
yocardium and fibrotic areas. Three or four specimens
ere analyzed for each patient. Low-power enlargement
as used to select appropriate areas for analysis, with
xclusion of subendocardial or perivascular areas with high
evels of collagen. Sites with marked scarring from previous
iopsies were also excluded because these areas were re-
arded as nonrepresentative fields. Once the appropriate
egions were selected, high-power magnification (200)
igital images were taken for all endomyocardial areas.
sing an automated image analysis system (Optimas 6.51,
edia Cybernetics, Bethesda, Maryland), we assessed col-
agen as a percentage of total endomyocardial area. Assess-
ent of collagen by this morphometric approach has been
hown to correlate well with myocardial levels of hy-
roxyproline (19).
MRI protocol. MAGNETIC RESONANCE IMAGING SE-
UENCES. We performed CMRI on 25 heart failure sub-
ects, 20 control subjects, and 9 subjects with previous heart
ransplantation, on a clinical 1.5-T CMRI scanner (Signa
D 1.5-T, GE Healthcare, Waukesha, Wisconsin). All
equences were acquired during a breath-hold of 10 to 15 s.
eft ventricular (LV) function was assessed by a steady state
ree precession pulse sequence (repetition time [TR] 3.8 ms,
Abbreviations
and Acronyms
CCF  congestive cardiac
failure
CMRI  cardiac magnetic
resonance imaging
DE  myocardium
without delayed
enhancement
DE  myocardium with
delayed enhancement
ECG  electrocardiogram
GFR  glomerular filtration
rate
ICMP  ischemic
cardiomyopathy
IDCM  idiopathic dilated
cardiomyopathy
LVEF  left ventricular
ejection fraction
ROI  region of interest
TTE  transthoracic
echocardiographycho time [TE] 1.6 ms, 30 phases, slice thickness 8 mm).
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Quantifying Fibrosis in Heart Failure November 4, 2008:1574–80Delayed hyperenhancement was obtained 10 min after a
olus of gadolinium-diethylene triamine penta-acetic acid
DTPA) (0.2 mmol/kg BW Magnevist, Schering, Ger-
any) to identify regional fibrosis using an inversion-
ecovery gradient echo technique (TR 7.1 ms, TE 3.1 ms,
nversion time [TI] individually determined to null the
yocardial signal, range 180 to 250 ms, slice thickness 8
m, matrix 256  192, number of acquisitions  2).
For evaluation of diffuse fibrosis, a prototype sequence
as used to cycle through acquisition of images over a range
f inversion times. The sequence consisted of an
lectrocardiogram-triggered, inversion-recovery prepared,
-dimensional fast gradient echo sequence employing vari-
ble temporal sampling of k-space (VAST) (20) (Global
pplied Science Laboratory, GE Healthcare). Ten images
ere acquired sequentially at increasing inversion times (50
o 1,000 ms) 15 min after the bolus of gadolinium-DTPA
entioned earlier, typically over a series of 3 to 4 breath-
olds. Imaging parameters were TR/TE: 3.7 ms/1.2 ms, flip
ngle: 20°, 256  128 acquisition matrix, 36  27-cm field
f view, 8-mm slice thickness, TI: 50 ms-1 s, trigger delay
00 ms, and views per segment 24. These images were then
rocessed with a curve fitting technique to generate T1 maps.
All cine CMRI sequences were performed in 3 standard
hort-axis slices (apical, mid, and basal), kept identical for
ach sequence throughout the CMRI examination (21).
rom an end-diastolic, 4-chamber, long-axis view, 5 equally
paced slices were planned, so that the 2 outer slices lined up
xactly either with the tip of the apex or the mitral annulus.
he 2 outer slices were then deleted, leaving 3 slices
orresponding to typical basal, mid, and apical short-axis
iews. Delayed enhancement imaging was performed in
oth long- and short-axis views. For T1 mapping, the
iddle slice short-axis slice was utilized.
valuation of LV function and regional fibrosis. LV
unction was evaluated globally using the biplane area-
ength method using 2- and 4-chamber long-axis views.
egional wall thickening was evaluated from the mid short
xis view by calculating percent systolic thickening.
Regional fibrosis was identified by delayed enhancement
ithin the myocardium, defined quantitatively by myocar-
ial post-contrast signal intensity2 SDs above that within
reference region of remote noninfarcted myocardium
ithin the same slice.
valuation of diffuse fibrosis with T1 mapping. Follow-
ng image acquisition, the 10 short-axis images of varying
nversion times were transferred to an external computer for
nalysis using a dedicated research software package (Cin-
tool, Global Applied Science Laboratory, GE Healthcare).
his provided the ability to analyze regions of interest
ROIs) to find average T1 for that area, as well as a
ixel-by-pixel determination of T1, by fitting data acquired
t various preparation times to the exponential curve: Mz
t  TI   M0A  Bet⁄T1, relating the sample magne-
ization Mz observed at the time t  TI to the equilibrium
agnetization M0 and sample T1, where TI denotes inversion mime for an inversion recovery experiment. For each image, an
OI was drawn around the entire myocardium to calculate
ost-contrast myocardial T1 time for each subject (Fig. 1). In
ubjects with regional fibrosis detected by delayed enhance-
ent, either due to infarction, mid-wall fibrosis from idio-
athic dilated cardiomyopathy (IDCM), or patchy nonvas-
ular distribution fibrosis from infiltrative cardiomyopathy,
n additional analysis was performed in which regions of
elayed enhancement were excluded from the ROI for
alculation of post-contrast myocardial T1 time. We also
erformed a third analysis in which the ROI was limited to
nly the region of myocardium with regional fibrosis on
elayed enhancement imaging. For calculation of skeletal
uscle T1 time, the ROI was drawn around the pectoralis
uscle.
valuation of diastolic function. Standard transthoracic
chocardiography was performed as a baseline evaluation of
ardiac morphology and function. Diastolic function was
ssessed by a combination of mitral flow inflow pattern
E to A ratio, deceleration time, and isovolumetric ventric-
lar relaxation time), as well as mitral annular velocity (E=).
n all cases an experienced cardiologist who was blinded to
he CMRI findings graded diastolic function according to
stablished guidelines (22,23). Diastolic function was ex-
ressed as either normal, impaired relaxation (including
oth delayed left ventricular relaxation and pseudo-
ormalization), or restrictive. Additionally, the mitral E/E=
as calculated as an index of ventricular filling pressure.
tatistics. All data are expressed as mean  1 standard
rror unless otherwise indicated. Comparison between
roups using continuous variables utilized unpaired Student
test. Comparison between multiple groups was performed
ith analysis of variance (ANOVA), with post hoc analysis
erformed as appropriate. Pairwise multiple comparisons
ere performed using the Holm-Sidak method. Dependent
ariables were correlated by calculating the Pearson Product
oment. For all comparisons, a p value of 0.05 was
onsidered significant.
esults
linical and demographic data. A total of 54 patients
ere evaluated in the study period. There were 25 patients
ith heart failure, 20 control subjects, and 9 heart transplant
ecipients (mean time after transplantation 1.7  1.2 years)
n whom histologic correlation of fibrosis with CMRI
ndings was obtained. Demographic data from the 45 heart
ailure and control subjects is presented in Table 1. Patients
n the heart failure group were older, and there was a trend
o an increased number of male subjects in the heart failure
roup (72% vs. 50%, p  0.13, chi-square). There was no
ifference in heart rate between heart failure and control
roups (mean heart rate 70  3.4 beats/min vs. 67  2.4
eats/min, p  NS), or in renal function (glomerular
ltration rate 76.0  13.6 ml/min/1.73 m2 vs. 81.3  12.1
l/min/1.73 m2, p  0.71). The heart failure group was
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November 4, 2008:1574–80 Quantifying Fibrosis in Heart Failureell represented across a range of etiologies, including
schemic cardiomyopathy (ICMP), infiltrative cardiomyop-
thy, and IDCM. In all subjects CMRI scanning proceeded
ithout complication, with the T1 mapping protocol suc-
essfully completed.
elationship of post-contrast myocardial T1 time to
yocardial interstitial fibrosis. To assess the correlation
etween post-contrast myocardial T1 time and collagen, we
valuated a separate group of post-transplant patients with
outine endomyocardial biopsies (Fig. 2). Collagen volume
raction ranged from 1.5% to 13.3% (mean 8.4 4.3%) and
ost-contrast myocardial T1 times from 314 to 656 ms
Figure 1 Calculating Myocardial T1 Time
A region of interest (ROI) was drawn around the left ventricular myocardium in the
were then curve-fitted to an exponential recovery curve to obtain the myocardial T1
to demonstrate regional fibrosis.
atient Demographics
Table 1 Patient Demographics
CCF
(n  25)
Control
(n  20) p Value
Age (yrs) 54 2.2 38 3.0 0.0001
Male, n (%) 18 (72) 10 (50) NS
Left ventricular ejection fraction (%) 35 3.3 66 1.4 0.0001
NYHA functional class 2.4 0.1 1.0 0 0.0001
Heart rate (beats/min) 70 3.4 67 2.4 NS
Heart failure etiology, n (%)
Ischemic cardiomyopathy 9 (36) — —
Idiopathic dilated cardiomyopathy 7 (28) — —
Restrictive/infiltrative 9 (36) — —s
alues expressed as mean standard error unless otherwise specified.
CCF  congestive cardiac failure; NYHA  New York Heart Association.mean 521.8  38.9 ms). Collagen content progressively
ncreased as post-contrast myocardial T1 times shortened
R  0.7, p  0.03), as shown in Figure 3.
lobal post-contrast myocardial T1 times in heart failure
nd control subjects. In subjects with heart failure, post-
ontrast myocardial T1 time was significantly shorter com-
ared with that in control subjects (383  17 ms in heart
ailure vs. 564  23 ms in control subjects, p  0.0001).
his difference remained highly significant when an aged-
atched cohort of the control group (n 10) was compared
ith heart failure subjects (383  17 ms in heart failure vs.
43  32 ms in control subjects, p  0.0001). Slower
yocardial clearance of contrast in heart failure due to
educed cardiac output is unlikely to account for this
ifference, as there was no significant difference in post-
ontrast skeletal muscle T1 time between heart failure and
ontrol subjects (564 55 ms vs. 521 27 ms, respectively,
 NS). There was also no difference in left ventricular
lood pool post-contrast T1 time between heart failure and
ontrol subjects (272  12 ms in heart failure vs. 286  7
s in control subjects, p  NS). In addition, in control and
eart failure subjects there was no correlation between heart
ate and post-contrast myocardial T1 time (R  0.14, p 
S). Prior to contrast administration, there was no difference
n myocardial T1 time between heart failure and control
ages obtained from our prototype sequence (A). Signal intensities for each ROI
for each patient (B). Conventional delayed enhancement imaging (C) was used10 im
timeubjects (874 74 ms vs. 975 62 ms, respectively, pNS).
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Quantifying Fibrosis in Heart Failure November 4, 2008:1574–80mpact of regional fibrosis on post-contrast myocardial
1 time. As expected, all 9 subjects with ischemic cardio-
yopathy had areas of delayed enhancement on post-
ontrast CMRI corresponding to regional fibrosis. Over half
f all subjects with nonischemic cardiomyopathy also had
egional fibrosis, with 5 of 7 subjects with IDCM, and 4 of
subjects with infiltrative cardiomyopathy demonstrating
elayed enhancement on post-contrast CMRI. Because the
resence of regional scarring will clearly affect global post-
ontrast myocardial T1 time, we further evaluated the
ubgroup of subjects with heart failure who had visible
egions of delayed enhancement on post-contrast CMRI. In
hese subjects, the myocardium was subdivided into two
reas: myocardium with and without delayed enhancement
Figure 2 Histologic Findings
Endomyocardial tissue from 2 patients showing minimal (A) and more extensive (
Sections were stained with picrosirius red with collagen identified in red and myoc
Figure 3 Myocardial Collagen Content and Post-Contrast T1 Times
Endomyocardial biopsy specimens from 9 subjects after cardiac transplantation
were stained with picrosirius red, and collagen content was calculated as a
percentage of total myocardial tissue. The post-contrast myocardial T1 time
shortened significantly as the myocardial collagen content increased
(r  0.7, p  0.03).DE and DE, respectively). Separate post-contrast T1
ecovery curves were then constructed in both DE and
E myocardium to separate the effect of regional fibrosis
rom global post-contrast T1 time.
Even in DE areas of myocardium, there was a marked
ifference in post-contrast myocardial T1 time between
eart failure and control subjects (429  22 ms in heart
ailure subjects vs. 564  23 ms in control subjects, p 
.0001) ( Fig. 4). As expected, there was also a difference in
ost-contrast T1 time between DE and DE myocar-
ium in heart failure subjects (333  30 ms in DE areas
s. 429  22 ms in DE areas, p  0.02) (Fig. 4),
onsistent with a higher degree of fibrosis in regions of
yocardium displaying delayed contrast enhancement.
rstitial fibrosis.
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Figure 4 Post-Contrast Myocardial T1 Times
The myocardium of subjects with heart failure (congestive cardiac failure [CCF])
and regional fibrosis detected by conventional delayed contrast-enhanced imag-
ing was divided into areas with (DE) and without (DE) regional scarring. The
post-contrast myocardial T1 time was significantly shorter in DE regions com-
pared with controls, consistent with diffuse fibrosis even in areas of myocar-
dium not displaying regional scarring (*p  0.0001). There was also a
difference in the post-contrast myocardial T1 time of heart failure subjects
between DE and DE areas of myocardium (†p  0.02).B) inte
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November 4, 2008:1574–80 Quantifying Fibrosis in Heart Failureelationship of post-contrast myocardial T1 time to
ystolic and diastolic function. Because diffuse fibrosis
ay contribute to diastolic dysfunction at a mechanistic
evel via increased myocardial stiffness, we evaluated the
elationship of post-contrast myocardial T1 time to conven-
ional echocardiographic assessment of LV diastolic func-
ion. When diastolic function was graded as normal, im-
aired, or restrictive there was progressive shortening of the
ost-contrast myocardial T1 time (562  24 ms in normal
iastolic function vs. 423  33 ms in impaired diastolic
unction vs. 368  20 ms in restrictive function, p  0.001
y ANOVA), consistent with worsening of diffuse fibrosis
cross diastolic function grades (Fig. 5). Post hoc analysis
evealed a significant difference in post-contrast myocardial
1 time between normal and both impaired relaxation (p 
.03) and restrictive groups (p  0.02), as well as a strong
rend to a difference between impaired and restrictive
iastolic function (p  0.05).
As expected, global systolic function and systolic thick-
ning were significantly reduced in heart failure subjects
ompared with control subjects (left ventricular ejection
raction 35  3% in heart failure subjects vs. 66  1% in
ontrol subjects, systolic thickening 38 4% in heart failure
ubjects vs. 79  4% in control subjects, p  0.0001 for
oth). However, we found no correlation between the
egree of fibrosis measured by the post-contrast myocardial
1 time and systolic thickening (R  0.32, p  NS).
inally, because progressive fibrosis has been implicated in
dverse remodeling in ischemic cardiomyopathy, we evalu-
ted the impact of diffuse fibrosis in DE regions of the 9
ubjects with heart failure due to ICMP. In these subjects,
ystolic thickening was significantly reduced in noninfarcted
egments compared with that in control subjects (36  6%
s. 79  4%, p  0.0001), consistent with adverse cardiac
emodeling of “healthy” myocardium as an important com-
onent of disease progression in ICMP.
Figure 5 Diastolic Function and Myocardial T1 Times
Post-contrast myocardial T1 time progressively shortened with worsening
grades of diastolic function (*p  0.001, analysis of variance).siscussion
ur data demonstrated profound differences in myocardial
ontrast accumulation between normal and heart failure
ubjects utilizing post-contrast T1 mapping, with histologic
ata supporting our assertion that these changes reflect
iffuse fibrosis. These differences remained in age-matched
roups, suggesting our findings are not explained by increas-
ng fibrosis with age. The differences also correlated with
chocardiographic measurements of diastolic function, in-
icating shortening of T1 time may reflect altered diastology
s a functional consequence of myocardial fibrosis.
Interestingly, marked changes in myocardial post-
ontrast T1 time were observed in heart failure subjects even
hen the analysis was limited to areas of myocardium
ithout delayed contrast enhancement. This underscores
he importance of calculating the myocardial post-contrast
1 value in such instances, as diffusely fibrotic myocardium
ay accumulate contrast not detectable by conventional
elayed enhanced CMRI. In addition, noninfarcted areas of
yocardium in patients with ICMP also demonstrated
educed systolic thickening, suggesting pathologic remod-
ling and fibrosis in these areas. Although pathologic
emodeling has been proposed as an important feature in
he progression of all types of cardiomyopathy (24–26), our
ata provide a method of monitoring its progression that
ould easily be used to evaluate and/or select future therapies
imed at its regression.
A number of limitations should be kept in mind when
nterpreting our data. This is a small population with
eterogeneous causes of heart failure. Gadolinium-based
ontrast has been shown to accumulate in the myocardium
n a number of conditions apart from heart failure, such as
rrhythmogenic right ventricular dysplasia, sarcoidosis, and
myloidosis. But in these conditions, delayed enhancement
s also thought to be due to the presence of fibrous tissue in
brofatty change, fibrotic reaction to granulomata, or amy-
oid deposition, respectively. Contrast accumulation has also
een demonstrated in acute myocarditis and infarction,
resumably due to local tissue and capillary destruction,
ith resultant slow clearance of contrast. Altered volume of
istribution in infarcted myocardium, due to loss of cellular
ntegrity, is a major element affecting gadolinium-based
ontrast accumulation. Our study did not include patients
ith recent infarction or myocarditis, so although caution
hould be used in applying our data to these patient groups,
his is unlikely to account for the changes we observed in our
tudy population.
A number of factors may influence gadolinium-DTPA
inetics. There was no significant difference in renal func-
ion between the control and heart failure groups, making
mpaired clearance an unlikely contributing factor. Al-
hough gadolinium-DTPA kinetics and volume of distribu-
ion may be altered in heart failure independent of renal
unction, skeletal muscle and left ventricular blood pool
erve as useful internal controls. Indeed, available data on
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Quantifying Fibrosis in Heart Failure November 4, 2008:1574–80keletal muscle changes in heart failure suggest both reduced
erfusion (27) and increasing fibrosis (28), both of which
ould result in impaired clearance of gadolinium-based
ontrast and therefore, shorter T1 times of skeletal muscle in
eart failure. The fact that we did not observe contrast
ccumulation in skeletal muscle in heart failure even though
ignificant accumulation occurred in the heart is consistent
ith a disproportionate amount of myocardial fibrosis.
here was also no difference in left ventricular blood pool
ost-contrast T1 time between heart failure and control
ubjects. Finally, variations in heart rate may affect measure-
ent of myocardial T1 time. In our study, mean heart rate
id not differ between heart failure and control groups, and
here was no correlation between heart rate and post-
ontrast myocardial T1 time in study subjects, excluding
eart rate as a significant confounder of our observations.
onclusions
ardiac failure is a major cause of morbidity and mortality
orldwide. The future challenge to scientists and clinicians
like is to gain a greater understanding of the underlying
isease processes to enable development of newer therapies
imed at impeding or reversing disease progression. CMRI
1 mapping is a promising modality for noninvasive evalu-
tion of diffuse myocardial fibrosis in heart failure, providing
mportant mechanistic insights into the relationship be-
ween myocardial fibrosis and diastolic dysfunction. Devel-
pment of CMRI as a noninvasive tool for evaluating
yocardial fibrosis in patients with cardiomyopathy will
urther our understanding of the underlying physiology and
linical course of heart failure.
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